PBRM1 alterations have also been clinically validated as marker of ICI responsiveness in RCC but the effect on response and survival is modest and has been mainly observed in the subset of patients who received prior antiangiogenic therapy [239]. Here, PBRM1 is linked to renal cell carcinoma.